813 results about "Hydroxybutyrates" patented technology

Several novel PHA polymer compositions produced using biological systems include monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. This can be accomplished by taking natural PHA producers and mutating through chemical or transposon mutagenesis to delete or inactivate genes encoding undesirable activities. Alternatively, the strains can be genetically engineered to express only those enzymes required for the production of the desired polymer composition. Methods for genetically engineering PHA producing microbes are widely known in the art (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53). These polymers have a variety of uses in medical, industrial and other commercial areas.

The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

The present invention provides a preparation method of (S)-4-hydroxyl-2-oxo-1-pyrrolidine acetamide. The preparation method comprises: (S)-4-halogen-3-hydroxyl butyric ester as a raw material reacts under the conditions with polar solvent and alkalinity to prepare the crude product of (S)-4-hydroxyl-2-oxo-1-pyrrolidine acetamide; and the crude product is purified. The preparation method is characterized in that inorganic alkali is added for a plurality of times in the reaction process under the condition with alkalinity so as to control the pH value in the reaction to be less than or equal to 8.5. A large quantity of repeated tests are completed to determine that the optimum pH value of the reaction under the condition with alkalinity is less than or equal to 8.5, and the alkali is added in batches to strictly control the pH value of the whole reaction process, so that the alkali conditions required in the reaction can be satisfied and the reaction can be performed completely, and the target product (S)-oxiracetam is prevented from being damaged in the alkaline solution, thereby improving the yield rate of the target product (S)-oxiracetam and reducing the cost.

Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available, and could offer additional benefits such as anti-adhesion properties, reduced risks of infection or other post-operative problems resulting from absorption and eventual elimination of the device, and competitive cost. The devices may also be particularly suitable for use in pediatric populations where their absorption should not hinder growth, and provide in all patient populations wound healing with long-term mechanical stability. The devices may additionally be combined with autologous, allogenic and/or xenogenic tissues to provide implants with improved mechanical, biological and handling properties.

The invention discloses a halomonas strain and application thereof. The halomonas strain is a halomonas sp. TD01 with a preservation number of CGMCC NO.4353. Experiments indicate that the halomonas sp. TD01 can effectively accumulate polyhydroxyalkanoates (PHA) in a mineral medium (MM) and provides a better guarantee for the biosynthesis of the PHA and PHBV (poly(hydroxybutyrate-hydroxyvalerate)). The halomonas strain has the advantages of simple nutrient requirement, no need of sterilization in a fermenting process, capability of continuous implantation and simpleness and easiness in control. Methods for preparing the PHA by using the halomonas sp. TD01 all lower the production cost from varying degrees and increase the yield of the PHA; and the obtained PHA has the molecular weight of above 500kDa and has an industrial application value.

Absorbable polyester fibers, braids, and surgical meshes with improved handling properties have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available and have a decreased tendency to curl, in the preferred embodiment, due to the inclusion of relaxation and annealing steps following extrusion and orientation of the fiber. Filaments prepared according to these methods are characterized by the following physical properties: (i) elongation to break from about 17% to about 85% (ii) Young's modulus of less than 350,000 psi, (iii) knot to straight ratio (knot strength/tensile strength) of 55-80% or (iv) load at break from 1100 to 4200 grams.

Blends of amorphous and semicrystalline polymers having shape memory properties were prepared by blending a crystalline polymer such as poly(vinylidene fluoride), polylactide, poly(hydroxxybutyrate), poly(ethylene glycol) polyethylene, polyethylene-co-vinyl acetate, poly(vinyl chloride), poly(vinylidene chloride) and copolymers of poly(vinylidene chloride) and poly(vinyle chloride) and an amorphous polymer such as poly(vinyl acetate), poly methyl acrylate, poly ethyl acrylate, atactic poly methyl methacrylate, isotactic poly methyl methacrylate, syndiotactic poly methyl methacrylate and other poly alkyl methacrylates. The method for preparing the polymeric materials and applications thereof, for example, as smart medical devices, are also disclosed.

Absorbable implants for breast surgery that conform to the breast parenchyma and surrounding chest wall have been developed. These implants support newly lifted breast parenchyma, and/or a breast implant. The implants have mechanical properties sufficient to support a reconstructed breast, and allow the in-growth of tissue into the implant as it degrades. The implants have a strength retention profile allowing the support of the breast to be transitioned from the implant to regenerated host tissue, without significant loss of support. Three-dimensional implants for use in minimally invasive mastopexy/breast reconstruction procedures are also described, that confer shape to a patient's breast. These implants are self-reinforced, can be temporarily deformed, implanted in a suitably dissected tissue plane, and resume their preformed three-dimensional shape. The implants are preferably made from poly-4-hydroxybutyrate (P4HB) and copolymers thereof. The implants have suture pullout strengths that can resist the mechanical loads exerted on the reconstructed breast.

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Recombinant hosts for producing polyhydroxyalkanoates and methods of producing polyhydroxyalkanoates from renewable carbon substrates are provided. Certain recombinant hosts that produce 5 carbon chemicals such as 5-aminopentanoate (5AP), 5-hydroxyvalerate (5HV), glutarate, and 1,5 pentanediol (PDO) are also provided. One embodiment provides a recombinant host expressing a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 5-hydroxyvalerate-CoA (5HV-CoA) transferase, wherein the host produces a polymer containing 5-hydroxyvalerate. Preferably, the host expresses both a polyhydroxyalkanoate synthase and a 5HV-CoA transferase. The host can be prokaryotic or eukaryotic. A preferred prokaryotic host is E. coli. The polymers produced by the recombinant hosts can be homopolymers or copolymers of 5-hydroxyvalerate. A preferred copolymer is poly(3-hydroxybutyrate-co-5-hydroxyvalerate).